India Is One of the World’s Most Obese Countries, But Few Indians Want GLP 1s
Bloomberg Television · 1:34
Cheap generic GLP-1s after Indian patent expiry have not produced the expected boom: at about $14 a month, demand is still held back by prescribing friction, disease classification, advertising limits, stigma, househo...